Loading company
PAVmed Inc.
PAVM · Nasdaq · ·
$3.82-2.6%Sep 29 close
- 1M
- -22.5%
- 6M
- -61.1%
- 1Y
- -70.5%
- 5Y
- -99.9%
PAVM · Nasdaq · ·
$3.82-2.6%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $33K | $6K | +450.00% |
| Profit | -$5.4M | -$11.9M | +54.84% |
| Profit per share | -$0.87 | -$1.19 | +26.89% |
| Free Cash Flow | -$2.7M | -$1.2M | -125.63% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
PAVmed Inc. has no earnings call transcript available.
“PAVmed saw tangible progress across its core businesses during this past quarter and recent weeks,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard ® Esophageal DNA Test and EsoCheck ® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from PAVmed Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.